HURA TuHURA Biosciences, Inc./NV
Pharmaceutical Preparations · Nasdaq · SEC CIK 1498382 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-2.2%
TTM EPS YoY-47.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-167.5%
ROA-96.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets47.7%
Debt / equity0.49x
Current ratio0.47x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.79x
Accruals ratio-20.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $3.70M | $6.62M | $5.23M | $6.06M | $4.97M | $4.93M | $4.58M | $3.98M |
| SG&A expense | $1.96M | $2.14M | $2.30M | -$1.56M | $1.59M | $1.86M | $2.02M | $1.72M |
| Interest expense | $752,509 | $467,634 | $27,974 | $608,751 | $16,532 | $0 | — | $522,835 |
| Net income | -$6.41M | -$9.22M | -$7.54M | -$6.76M | -$7.10M | -$9.52M | -$6.66M | -$6.00M |
| EPS (basic) | -0.10 | -0.14 | -0.13 | — | -0.14 | -0.21 | -0.15 | — |
| EPS (diluted) | -0.10 | -0.14 | -0.13 | — | -0.14 | -0.21 | -0.15 | — |
| Weighted avg. shares (diluted) | 65.00M | 63.96M | 60.01M | — | 50.67M | 44.56M | 43.40M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $1.89M | $995,977 | $6.30M | $3.62M | $2.70M | $8.51M | $6.22M | $12.66M |
| Current assets | $3.68M | $1.66M | $6.98M | $4.62M | $3.50M | $12.54M | $14.33M | $19.61M |
| PP&E, net | $407,794 | $434,887 | $326,012 | $300,639 | $295,332 | $144,171 | $151,980 | $123,366 |
| Goodwill | $10.74M | $10.74M | $10.74M | $10.74M | $13.55M | $13.55M | — | — |
| Total assets | $36.24M | $31.75M | $29.70M | $27.35M | $25.70M | $34.62M | $14.64M | $19.97M |
| Current liabilities | $7.76M | $9.26M | $6.07M | $5.92M | $8.83M | $15.17M | $4.78M | $5.33M |
| Long-term debt | $9.20M | $3.60M | — | — | — | — | — | — |
| Total debt | $9.20M | $3.60M | — | — | — | — | — | — |
| Total liabilities | $17.29M | $13.25M | $6.51M | $6.42M | $8.92M | $15.17M | $4.78M | $5.37M |
| Shareholders' equity | $18.95M | $18.50M | $23.19M | $20.93M | $16.78M | $19.45M | $9.86M | $14.59M |
| Net debt | $7.31M | $2.60M | — | — | — | — | — | — |
| Shares outstanding | 65.76M | 63.68M | 63.58M | 59.34M | 51.25M | 49.91M | 43.68M | 12.17M |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.01M | -$8.63M | -$4.41M | -$5.56M | -$11.09M | -$6.25M | -$4.74M | -$2.60M |
| Capital expenditure | $0 | $136,978 | $48,846 | $27,850 | $0 | $5,561 | $42,672 | $21,408 |
| Free cash flow | -$5.01M | -$8.77M | -$4.46M | -$5.58M | -$11.09M | -$6.25M | -$4.78M | -$2.62M |
| Investing cash flow | $0 | -$136,978 | -$48,846 | -$27,850 | $0 | -$156,464 | -$1.15M | -$823,540 |
| Financing cash flow | $5.91M | $3.47M | $7.14M | $6.51M | $5.27M | $8.70M | -$547,878 | -$3.52M |
| Depreciation & amortization | $27,000 | $28,000 | $23,472 | $22,544 | $21,000 | $14,000 | $14,058 | $17,635 |
| Stock-based compensation | $1.42M | $2.14M | $2.80M | $2.15M | $1.45M | $1.41M | $1.42M | $1.08M |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.